Workflow
ER-KANG(300267)
icon
Search documents
双主业协同发力 尔康制药上半年净利润同比增长近5倍
Zheng Quan Ri Bao Wang· 2025-08-27 13:44
Core Viewpoint - Hunan Erkang Pharmaceutical Co., Ltd. reported significant growth in its 2025 semi-annual results, with a revenue of 680 million yuan, a year-on-year increase of 9.74%, and a net profit of 37.63 million yuan, reflecting a substantial year-on-year growth of 497.36% [1] Pharmaceutical Sector - The company is focusing on innovation and international development, successfully entering the African market with a new production project in Tanzania, involving an investment of 10 million USD to upgrade local facilities for solid dosage forms [1] - The company has achieved significant milestones in its pharmaceutical sector, including the successful evaluation of its Vitamin B6 injection for consistency and obtaining a drug registration certificate for theobromine injection [1] New Energy Materials Sector - The new energy materials segment generated revenue of 127 million yuan, accounting for 18.57% of total revenue, establishing itself as a crucial business support and second growth curve for the company [2] - The company has improved operational efficiency at its Nigerian mining facility, enhancing daily processing capacity and lithium recovery rates [2] Future Outlook - The company plans to continue focusing on its core strategies, consolidating domestic advantages while accelerating the development of its pharmaceutical and new energy businesses in Africa, aiming to optimize talent structure and operational efficiency to achieve annual business goals [2]
尔康制药双主业协同发力 上半年净利润同比增长近5倍
Core Insights - The company reported a revenue of 680 million yuan for the first half of 2025, representing a year-on-year growth of 9.74%, and a net profit of 37.63 million yuan, which is a significant increase of 497.36% compared to the previous year [1] - The company is focusing on its core business areas and has made substantial progress in both the pharmaceutical and new energy materials sectors, which is expected to enhance long-term investment value [1][2] Pharmaceutical Sector - The company has initiated a comprehensive formulation production project in Tanzania, planning to invest 10 million USD to upgrade existing facilities and build a solid dosage production line that meets international standards [1] - The successful completion of this project is anticipated to open new avenues for growth in the African pharmaceutical market and positively impact the company's operational scale and performance [1] - The company has also achieved significant milestones in innovation, including the approval of its Vitamin B6 injection for consistency evaluation and obtaining a drug registration certificate for theobromine injection [1] New Energy Materials Sector - The new energy materials segment generated a revenue of 127 million yuan, showing significant year-on-year growth and accounting for 18.57% of the company's total revenue, establishing itself as a crucial support for the company's growth [2] - The company has improved the operational stability of its Nigerian mining plant through enhanced personnel training and equipment management, leading to increased daily processing capacity and lithium recovery rates [2] Future Outlook - The company plans to continue focusing on its core strategies while consolidating its domestic business advantages and accelerating the development of its pharmaceutical and new energy businesses in Africa [2] - Efforts will be made to optimize talent structure and operational efficiency to achieve annual business goals and create greater value for shareholders [2]
尔康制药:双主业协同发力,上半年净利润同比增长近5倍
Quan Jing Wang· 2025-08-27 12:45
Core Viewpoint - Erkang Pharmaceutical reported significant growth in both revenue and net profit for the first half of 2025, indicating a strong performance and strategic focus on core business areas and international expansion [1][2] Group 1: Financial Performance - The company achieved a revenue of 680 million yuan, representing a year-on-year increase of 9.74% [1] - Net profit reached 37.63 million yuan, showing a substantial year-on-year growth of 497.36% [1] Group 2: Pharmaceutical Sector Developments - Erkang Pharmaceutical is actively pursuing innovation and internationalization in the pharmaceutical sector, successfully entering the African market [1] - The company has initiated a comprehensive formulation production project in Tanzania, with an investment of 10 million USD to upgrade local facilities and build a solid dosage production line [1] - The successful completion of this project is expected to enhance the company's presence in the African pharmaceutical industry and create new profit growth points [1] Group 3: New Energy Materials Progress - The new energy materials segment generated revenue of 127 million yuan, showing significant year-on-year growth and accounting for 18.57% of total revenue [2] - The company has improved operational stability at its Nigerian mining facility, enhancing daily processing capacity and lithium recovery rates [2] Group 4: Future Outlook - Looking ahead, the company plans to continue focusing on its core strategies while accelerating the development of its pharmaceutical and new energy businesses in Africa [2] - The company aims to optimize talent structure and operational efficiency to achieve its annual business goals and create greater value for shareholders [2]
尔康制药(300267) - 关于聘任证券事务代表的公告
2025-08-27 12:35
证券代码:300267 证券简称:尔康制药 公告编号:2025-025 湖南尔康制药股份有限公司 关于聘任证券事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 湖南尔康制药股份有限公司(以下简称"公司")于 2025 年 8 月 27 日召开 的第五届董事会第十五次会议审议通过了《关于聘任证券事务代表的议案》,董 事会同意聘任王蓉女士(简历详见附件)担任公司证券事务代表,协助董事会秘 书开展工作,任期自本次会议审议通过之日起至第五届董事会届满之日止。 王蓉女士已经取得深圳证券交易所颁发的上市公司董事会秘书资格证书,具 备担任公司证券事务代表所必需的工作经验和专业知识,其任职资格符合《深圳 证券交易所创业板股票上市规则》的有关规定。 王蓉女士联系方式如下: 办公电话:0731-83282597 传 真:0731-83282705 电子邮箱:wangrong@hnerkang.com 特此公告! 湖南尔康制药股份有限公司 董 事 会 二〇二五年八月二十七日 附件: 王蓉女士简历 王蓉女士,1989 年出生,中国国籍,无境外永久居留权,硕士研究生学历。 ...
尔康制药(300267) - 2025年半年度非经营性资金占用及其他关联资金往来情况汇总表
2025-08-27 12:35
湖南尔康制药股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位:湖南尔康制药股份有限公司 单位:人民币万元 | 非经营性资金占用 | 资金占用方名称 | | 占用方与上 | 上市公司核算的 | 2025 年期初占 | 2025 年 1-6 | 月占用累 2025 | 年 1-6 月占 | 2025 年 1-6 月 | 2025 年 6 月 | 占用形 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 市公司的关 | 会计科目 | 用资金余额 | 计发生金额(不含利 | | 用资金的利息 | 偿还累计发 | 末占用资金 | 成原因 | | | | | | 联关系 | | | 息) | | (如有) | 生金额 | 余额 | | | | 控股股东、实际控制人及 | | | | | | | | | | | | 非经营性占用 | | 其附属企业 | | | | | | | | | | | | 非经营性占用 | | 小计 | | - | - ...
尔康制药(300267) - 董事会决议公告
2025-08-27 12:30
证券代码:300267 证券简称:尔康制药 公告编号:2025-022 经审议,董事会认为:公司 2025 年半年度报告及其摘要的编制程序、内容 和格式符合相关文件的规定;2025 年半年度报告编制期间,未有泄密及其他违 反法律法规或损害公司利益的行为发生;公司的财务报告真实、准确、完整地反 映了公司的财务状况和经营成果,不存在任何虚假记载、误导性陈述或者重大遗 漏。 公司 2025 年半年度报告及其摘要具体内容详见中国证监会指定信息披露网 站。 本议案已经公司董事会审计委员会审议通过,同意将本议案提交董事会审议。 表决结果:同意票 7 票;反对票 0 票;弃权票 0 票。 二、审议通过了《关于聘任证券事务代表的议案》 经审议,董事会同意聘任王蓉女士担任公司证券事务代表,协助董事会秘书 开展工作,任期自本次会议审议通过之日起至第五届董事会届满之日止。 湖南尔康制药股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 湖南尔康制药股份有限公司(以下简称"公司")第五届董事会第十五次会 议于 2025 年 8 月 27 日 ...
尔康制药:2025年上半年净利润同比增长497.36%
Xin Lang Cai Jing· 2025-08-27 12:23
尔康制药公告,2025年上半年营业收入6.82亿元,同比增长9.74%。净利润3763.46万元,同比增长 497.36%。 ...
尔康制药(300267) - 2025 Q2 - 季度财报
2025-08-27 12:20
[Part I Important Notice, Table of Contents, and Definitions](index=2&type=section&id=第一节%20重要提示、目录和释义) This section provides essential disclaimers, outlines the report's structure, and defines key terms for clarity [Important Notice](index=2&type=section&id=重要提示) The company's board, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report, and the financial report - The company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report content[3](index=3&type=chunk) - The company's responsible person, head of accounting work, and head of accounting department declare and guarantee the truthfulness, accuracy, and completeness of the financial report[3](index=3&type=chunk) - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the semi-annual period[4](index=4&type=chunk) [Table of Contents](index=3&type=section&id=目录) This section lists the overall structure of the report, including eight main chapters covering company operations and financial aspects - The report is divided into eight main chapters, covering various aspects of the company's operations and finances[6](index=6&type=chunk) [Definitions](index=5&type=section&id=释义) This section provides definitions for common terms and abbreviations of the company and its main subsidiaries used in the report to ensure clear understanding - This section defines the company, subsidiaries, and key terms such as "Company," "Erkang Pharmaceutical," and "Reporting Period" involved in the report[9](index=9&type=chunk) [Part II Company Profile and Key Financial Indicators](index=6&type=section&id=第二节%20公司简介和主要财务指标) This section presents the company's fundamental information and a summary of its key financial performance metrics [1. Company Profile](index=6&type=section&id=一、公司简介) This section introduces the company's basic information, including stock abbreviation, code, listing exchange, Chinese and English names, and legal representative Company Basic Information | Indicator | Content | | :--- | :--- | | Stock Abbreviation | Erkang Pharmaceutical | | Stock Code | 300267 | | Listing Stock Exchange | Shenzhen Stock Exchange | | Chinese Name | Hunan Erkang Pharmaceutical Co., Ltd. | | Legal Representative | Sun Qingrong | [2. Contact Persons and Information](index=6&type=section&id=二、联系人和联系方式) This section provides contact information for the company's Board Secretary and Securities Affairs Representative, including names, addresses, phone numbers, faxes, and email addresses - The company's Board Secretary is Gu Jishun, and the Securities Affairs Representative is Wang Rong, with the contact address for both being No. 1 Industrial Road, Kaiyuan Avenue, North Park, Liuyang Economic Development Zone, Changsha City[12](index=12&type=chunk) [3. Other Information](index=6&type=section&id=三、其他情况) During the reporting period, there were no changes in the company's registered address, office address, website, email, information disclosure and document storage locations, or registration status - The company's contact information, information disclosure and document storage locations, and registration status remained unchanged during the reporting period[13](index=13&type=chunk)[14](index=14&type=chunk)[15](index=15&type=chunk) [4. Key Accounting Data and Financial Indicators](index=7&type=section&id=四、主要会计数据和财务指标) This section discloses the company's key accounting data and financial indicators for the first half of 2025, showing a 9.74% year-over-year increase in operating revenue, a significant 497.36% increase in net profit attributable to shareholders, but a 64.08% year-over-year decrease in net cash flow from operating activities Key Accounting Data and Financial Indicators (Current Reporting Period vs. Prior Year Period) | Indicator | Current Reporting Period (RMB) | Prior Year Period (RMB) | Year-over-year Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 681,881,688.38 | 621,346,708.93 | 9.74% | | Net Profit Attributable to Shareholders of the Listed Company | 37,634,642.58 | 6,300,155.19 | 497.36% | | Net Profit Attributable to Shareholders of the Listed Company After Deducting Non-recurring Gains and Losses | 33,018,734.45 | 2,264,705.88 | 1,357.97% | | Net Cash Flow from Operating Activities | 45,842,247.53 | 127,628,976.65 | -64.08% | | Basic Earnings Per Share (RMB/share) | 0.0182 | 0.0031 | 487.10% | | Diluted Earnings Per Share (RMB/share) | 0.0182 | 0.0031 | 487.10% | | Weighted Average Return on Net Assets | 0.85% | 0.13% | 0.72% | | Total Assets (Period-end) | 5,049,890,880.73 | 5,199,734,491.19 (Prior Year-end) | -2.88% | | Net Assets Attributable to Shareholders of the Listed Company (Period-end) | 4,469,540,895.52 | 4,447,425,532.36 (Prior Year-end) | 0.50% | [5. Differences in Accounting Data Under Domestic and Overseas Accounting Standards](index=7&type=section&id=五、境内外会计准则下会计数据差异) During the reporting period, the company had no differences in net profit and net assets disclosed under International Accounting Standards or overseas accounting standards compared to Chinese Accounting Standards - The company had no differences in accounting data under domestic and overseas accounting standards during the reporting period[17](index=17&type=chunk)[18](index=18&type=chunk) [6. Non-recurring Gains and Losses Items and Amounts](index=7&type=section&id=六、非经常性损益项目及金额) This section lists the company's non-recurring gains and losses items and their amounts for the reporting period, totaling **RMB 4.62 million**, primarily including gains/losses from disposal of non-current assets, government grants, and entrusted investment gains/losses Non-recurring Gains and Losses Items and Amounts | Item | Amount (RMB) | | :--- | :--- | | Gains and Losses from Disposal of Non-current Assets | 323,099.98 | | Government Grants Recognized in Current Profit or Loss | 1,334,436.61 | | Gains and Losses from Entrusted Investments or Asset Management | 2,898,851.97 | | Other Non-operating Income and Expenses Apart from the Above | -58,665.88 | | Less: Income Tax Impact | -98,574.01 | | Impact on Minority Interests (after tax) | -19,611.44 | | Total | 4,615,908.13 | [Part III Management Discussion and Analysis](index=9&type=section&id=第三节%20管理层讨论与分析) This section provides an in-depth analysis of the company's business operations, financial performance, and strategic outlook [1. Principal Business Activities During the Reporting Period](index=9&type=section&id=一、报告期内公司从事的主要业务) The company's main business covers the production and sales of excipients, APIs, finished drugs, and new energy materials, with stable pharmaceutical performance and significant new energy growth - The company's main business includes the production and sales of excipients, APIs, finished drugs, and new energy materials[23](index=23&type=chunk) - In the first half of 2025, the company's pharmaceutical industry performance remained relatively stable, while the new energy industry performance significantly increased year-over-year[33](index=33&type=chunk) - The company officially launched the Tanzania comprehensive formulation production project, planning to invest **USD 10 million** to expand its business reach and create new profit growth points[52](index=52&type=chunk) - The Nigerian first beneficiation plant continuously increased capacity, with daily raw ore processing capacity and overall lithium recovery rate further improved during the reporting period, achieving new energy sector operating revenue of **RMB 126.60 million**[53](index=53&type=chunk) [1.1. General Situation](index=9&type=section&id=1、基本情况) The company's business covers pharmaceutical excipients, active pharmaceutical ingredients, finished drugs, and new energy materials production and sales - The company is the supporting unit for the National Engineering Research Center for Pharmaceutical Excipients, with a product line covering pharmaceutical solvents, stabilizers, sucrose, starch, starch capsules, and compound excipients[24](index=24&type=chunk) - The company's main API products are sulfadiazine and resorcinol[26](index=26&type=chunk) - The finished drug business involves production and circulation, with products including antibacterial, hemostatic, antitussive, and antiasthmatic injections, as well as traditional Chinese medicines for kidney disease, stomach ailments, and nourishing and calming purposes[27](index=27&type=chunk) - The company's new energy material varieties are primarily lithium carbonate and spodumene concentrate, continuously expanding its upstream layout in the lithium carbonate industry chain[28](index=28&type=chunk) [1.2. Business Model](index=9&type=section&id=2、经营模式) The company adopts a "production-to-order" model, with procurement handled by the supply department and business unit procurement centers, implementing proactive stocking strategies to counter rising raw material prices, and sales are primarily direct, supplemented by distribution - The company adopts a "production-to-order" model for production planning, with the quality department supervising and inspecting the production process[30](index=30&type=chunk) - The procurement model is managed by the supply department and various business unit procurement centers, which monitor market conditions and adjust procurement strategies accordingly[31](index=31&type=chunk) - The company's products are sold primarily through direct sales, supplemented by distribution[32](index=32&type=chunk) [1.3. Performance Drivers](index=10&type=section&id=3、业绩驱动因素) The company's performance is primarily driven by product structure optimization and sales model improvements in the pharmaceutical industry, as well as the commissioning, production process improvements, and capacity enhancements of the Nigerian beneficiation plant in the new energy industry - The company maintained stable performance in the pharmaceutical industry by optimizing its sales organizational structure, improving sales models, and adjusting product structure[33](index=33&type=chunk) - Following the commissioning of Erkang Mining's first beneficiation plant in Nigeria, production efficiency and output continuously improved through enhanced production processes, strengthened management, and training, driving significant performance growth in the new energy industry[33](index=33&type=chunk) [1.4. Industry Overview](index=10&type=section&id=4、行业情况) The pharmaceutical industry faces overall pressure but policy dividends are accelerating, with the pharmaceutical excipient industry moving towards high-quality development, and long-term energy storage demand expected to be the main engine for new energy materials - In the first half of 2025, operating revenue in the pharmaceutical manufacturing industry decreased by **1.2%** year-over-year, and total profit decreased by **2.8%** year-over-year, indicating overall industry pressure[34](index=34&type=chunk) - Guided by policies, the pharmaceutical excipient industry is developing towards "high standards, strong innovation, and rapid integration," with technological innovation and domestic substitution as core drivers[36](index=36&type=chunk) - In the first half of 2025, lithium carbonate prices fluctuated sharply, but China's lithium battery shipments increased by **68%** year-over-year, with power batteries growing by **49%** and energy storage batteries by **128%**[37](index=37&type=chunk)[38](index=38&type=chunk) - Pharmaceutical industry policies supporting innovative drug development will stimulate demand for high-end excipients, promote industry quality upgrades, and accelerate industry differentiation[39](index=39&type=chunk) - AI technology is expected to profoundly reshape the pharmaceutical excipient field, enabling efficient and intelligent screening and formulation optimization[43](index=43&type=chunk) - The new energy materials industry faces short-term capacity rationalization, but in the long term, driven by new energy vehicles and energy storage demand, core industry competition will shift towards resource endowment and technological barriers[45](index=45&type=chunk) [1.5. Company's Industry Position](index=13&type=section&id=5、公司所处行业地位) The company holds a significant position in the pharmaceutical excipient industry with 127 varieties covering common excipients and a national-level research platform, demonstrating strong market scale and R&D capabilities, and aims to become a high-quality new energy material supplier through its overseas lithium mine resource布局 - The company possesses **127** pharmaceutical excipient varieties, accounting for **32.87%** of the varieties included in the "Chinese Pharmacopoeia" (2025 edition), essentially covering all commonly used pharmaceutical excipient varieties[48](index=48&type=chunk) - The company owns national-level scientific research platforms such as the "National Engineering Research Center for Pharmaceutical Excipients" and actively participates in the revision and establishment of pharmaceutical excipient standards[48](index=48&type=chunk) - Erkang Mining, the company's wholly-owned subsidiary in Nigeria, has officially commenced operation of its beneficiation plant project, striving to become a "high-quality new energy material supplier"[49](index=49&type=chunk) [1.6. Business Operations](index=13&type=section&id=6、经营情况) In the first half of 2025, the company deepened its focus on pharmaceutical excipients, strengthened quality control and customer service; expanded into the African Tanzania pharmaceutical market by launching a comprehensive formulation production project; achieved stable production and increased efficiency in the new energy sector, improving daily raw ore processing capacity and overall lithium recovery rate; and strengthened talent management to support overseas operations - The company's pharmaceutical excipient segment established a strict quality control system, deepened customer service and technical collaboration, and strengthened its sales team development[50](index=50&type=chunk)[51](index=51&type=chunk) - The company launched a comprehensive formulation production project in Tanzania, planning to invest **USD 10 million** to build an international standard solid formulation production line[52](index=52&type=chunk) - The new energy materials business team enhanced personnel training and equipment inspection, continuously increasing capacity, with the new energy sector achieving operating revenue of **RMB 126.60 million** during the reporting period[53](index=53&type=chunk) - The company strengthened the introduction, training, and allocation of overseas talent, improved its incentive system, and built an online learning platform to provide talent support for its overseas business[54](index=54&type=chunk) [2. Core Competitiveness Analysis](index=14&type=section&id=二、核心竞争力分析) The company's core competitiveness lies in its R&D platforms, rich product portfolio, continuous technological innovation, comprehensive marketing network, and "pharmaceutical + new energy" dual-industry synergistic development strategy - The company possesses national-level scientific research platforms such as the "National Engineering Research Center for Pharmaceutical Excipients," dedicated to in-depth development of pharmaceutical excipients and research into new excipients[55](index=55&type=chunk) - The company boasts a rich product portfolio, including **127** pharmaceutical excipient varieties, **73** approved API varieties, and **283** finished drug approval numbers[56](index=56&type=chunk) - The company has significant technological innovation advantages, having independently developed products like hydroxypropyl starch empty capsules, which won first and second prizes in the Hunan Provincial Science and Technology Progress Awards[57](index=57&type=chunk) - The company has established a sales and distribution network with its headquarters as the marketing center and various offices as hubs, providing customized solutions and full-process technical support[58](index=58&type=chunk) - The company actively promotes an integrated "API + excipient + formulation" business ecosystem and expands into the new energy materials sector, achieving synergistic development of "pharmaceutical + new energy" dual industries[59](index=59&type=chunk) [3. Main Business Analysis](index=16&type=section&id=三、主营业务分析) The company's main business analysis shows that during the reporting period, operating revenue increased by 9.74% year-over-year, but operating costs increased by 14.29%, while selling expenses significantly decreased by 50.66%, with the new energy sector showing outstanding revenue and gross profit margin performance Key Financial Data Year-over-year Change | Indicator | Current Reporting Period (RMB) | Prior Year Period (RMB) | Year-over-year Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 681,881,688.38 | 621,346,708.93 | 9.74% | - | | Operating Cost | 494,458,519.80 | 432,636,194.26 | 14.29% | - | | Selling Expenses | 23,743,816.68 | 48,118,814.41 | -50.66% | Primarily due to reduced finished drug promotion expenses in this period | | Financial Expenses | 1,427,758.57 | -1,637,240.58 | 187.21% | Primarily due to reduced exchange gains in this period | | Net Cash Flow from Operating Activities | 45,842,247.53 | 127,628,976.65 | -64.08% | Primarily due to reduced net purchases and sales of goods in this period | Products or Services Accounting for Over 10% of Revenue | Product or Service Segment | Operating Revenue (RMB) | Operating Cost (RMB) | Gross Profit Margin | Year-over-year Change in Operating Revenue | | :--- | :--- | :--- | :--- | :--- | | Pharmaceutical Industry | 541,286,135.82 | 403,136,695.11 | 25.52% | -10.96% | | New Energy Industry | 126,602,224.59 | 80,703,326.37 | 36.25% | - | | Excipients | 455,795,458.91 | 358,347,363.68 | 21.38% | -4.66% | | New Energy Materials | 126,602,224.59 | 80,703,326.37 | 36.25% | - | | APIs | 46,736,991.76 | 25,512,237.08 | 45.41% | 15.44% | | Finished Drugs | 38,753,685.15 | 19,277,094.35 | 50.26% | -56.64% | [4. Non-Principal Business Analysis](index=17&type=section&id=四、非主营业务分析) The company had no non-principal business analysis during the reporting period - The company had no non-principal business analysis during the reporting period[65](index=65&type=chunk) [5. Analysis of Assets and Liabilities](index=17&type=section&id=五、资产及负债状况分析) At the end of the reporting period, the company's total assets decreased by 2.88% year-over-year, while net assets attributable to shareholders increased by 0.50%, with monetary funds, trading financial assets, and short-term borrowings decreasing, and accounts receivable, other current assets, and lease liabilities increasing Significant Changes in Asset Composition | Item | Amount at End of Current Reporting Period (RMB) | Percentage of Total Assets at End of Current Reporting Period | Amount at End of Prior Year (RMB) | Percentage of Total Assets at End of Prior Year | Change in Proportion | | :--- | :--- | :--- | :--- | :--- | :--- | | Monetary Funds | 492,515,859.62 | 9.75% | 698,537,949.74 | 13.43% | -3.68% | | Accounts Receivable | 162,703,385.26 | 3.22% | 103,181,869.28 | 1.98% | 1.24% | | Other Current Assets | 177,773,363.42 | 3.52% | 72,417,167.53 | 1.39% | 2.13% | | Short-term Borrowings | 310,082,500.00 | 6.14% | 488,198,472.23 | 9.39% | -3.25% | | Lease Liabilities | 28,693,744.25 | 0.57% | 17,375,180.58 | 0.33% | 0.24% | - The company's major overseas assets include Erkang Cambodia, Fenghuang Industrial, Wangkang Biochemical, and Erkang Mining, with Fenghuang Industrial having the largest asset scale, accounting for **25.75%** of the company's net assets[67](index=67&type=chunk) - As of the end of the reporting period, the company had restricted monetary funds of **RMB 129.18 million** and frozen land, properties, etc., with a book value of **RMB 404.83 million**[72](index=72&type=chunk) [6. Investment Analysis](index=19&type=section&id=六、投资状况分析) During the reporting period, the company's investment amounted to **RMB 27.48 million**, with entrusted wealth management totaling **RMB 175 million** and no overdue unrecovered amounts, and no derivative investments or entrusted loans Investment Amount for the Reporting Period | Indicator | Amount (RMB) | | :--- | :--- | | Investment Amount for the Reporting Period | 27,475,415.00 | | Investment Amount for the Prior Year Period | 0.00 | Entrusted Wealth Management | Specific Type | Entrusted Wealth Management Amount (RMB 10,000) | Outstanding Balance (RMB 10,000) | Overdue Unrecovered Amount (RMB 10,000) | | :--- | :--- | :--- | :--- | | Bank Wealth Management Products | 17,500 | 17,500 | 0 | - The company had no significant equity investments, significant non-equity investments, derivative investments, or entrusted loans during the reporting period[74](index=74&type=chunk)[77](index=77&type=chunk)[79](index=79&type=chunk)[80](index=80&type=chunk) [7. Significant Asset and Equity Disposals](index=20&type=section&id=七、重大资产和股权出售) The company did not have any significant asset or equity disposals during the reporting period - The company did not dispose of significant assets or equity during the reporting period[81](index=81&type=chunk)[82](index=82&type=chunk) [8. Analysis of Major Holding and Participating Companies](index=21&type=section&id=八、主要控股参股公司分析) This section lists the financial information of the company's major holding and participating companies, including total assets, net assets, operating revenue, and net profit, and notes the deregistration of one subsidiary and establishment of two new ones Major Subsidiaries and Participating Companies with Over 10% Impact on Company's Net Profit | Company Name | Company Type | Registered Capital | Total Assets (RMB) | Net Assets (RMB) | Operating Revenue (RMB) | Net Profit (RMB) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Xiangyikang | Subsidiary | RMB 10 million | 740,797,461.42 | 672,798,933.37 | 91,469,200.31 | 16,827,961.30 | | Hong Kong Erkang | Subsidiary | HKD 10,000 | 2,145,113,609.11 | 4,665,187.47 | 362,471,241.32 | 35,592,478.48 | | Wangkang Biochemical | Sub-subsidiary | USD 10 million | 100,579,415.18 | -58,878,503.70 | 7,466,985.55 | -8,218,642.36 | | Fenghuang Industrial | Sub-subsidiary | USD 10 million | 1,158,588,992.24 | -852,275,619.49 | 17,132,658.21 | -30,524,936.51 | | Guangyu Limin | Subsidiary | RMB 6.6 million | 176,249,318.99 | -51,794,756.31 | 13,521,672.92 | -8,628,867.52 | - During the reporting period, the company deregistered Yiyang Datonghu Suyikang Pharmaceutical Co., Ltd. and invested in establishing Hunan Guanhe Technology Co., Ltd. and Hangzhou Langde Intelligent Technology Co., Ltd.[84](index=84&type=chunk) [9. Structured Entities Controlled by the Company](index=21&type=section&id=九、公司控制的结构化主体情况) The company had no structured entities under its control during the reporting period - The company had no structured entities under its control during the reporting period[84](index=84&type=chunk) [10. Risks Faced by the Company and Countermeasures](index=22&type=section&id=十、公司面临的风险和应对措施) The company faces risks such as economic policy changes in individual countries, strategic layout management, raw material price fluctuations, and exchange rate volatility, and actively responds through various mitigation measures - The company's lithium mine beneficiation plant and comprehensive formulation production project in Africa may be affected by local economic policies and environmental changes[85](index=85&type=chunk) - The company's dual-main business transformation to "pharmaceutical industry + new energy industry" and business expansion into the African continent have increased strategic layout management risks[86](index=86&type=chunk) - Increased raw material procurement volume and cycles, influenced by macroeconomic and monetary policies, pose a risk of significant price fluctuations[87](index=87&type=chunk) - Increased international business volume leads to a larger scale of foreign exchange settlement, exposing the company to exchange rate fluctuation risks[88](index=88&type=chunk) - The company addresses risks through regular risk assessments, establishing government and community relations, introducing professional talent, optimizing the supply chain, and conducting hedging activities[85](index=85&type=chunk)[86](index=86&type=chunk)[87](index=87&type=chunk)[89](index=89&type=chunk) [11. Registration Form for Research, Communication, Interview, and Other Activities During the Reporting Period](index=23&type=section&id=十一、报告期内接待调研、沟通、采访等活动登记表) During the reporting period, the company hosted on-site research from various institutions and participated in online performance briefings, discussing strategic planning, operational plans, R&D investment, project progress, and overseas business development - On April 24, 2025, the company hosted on-site research from institutions such as Huayuan Securities and Huachuang Securities, discussing the company's strategic planning, operational plans, R&D investment, and project progress[90](index=90&type=chunk) - On May 12, 2025, the company participated in an online performance briefing via a network platform, discussing its strategic planning, operational goals and plans, and overseas business development[90](index=90&type=chunk) [12. Formulation and Implementation of Market Value Management System and Valuation Enhancement Plan](index=23&type=section&id=十二、市值管理制度和估值提升计划的制定落实情况) The company's board of directors approved the "Market Value Management System" on April 22, 2025, but no valuation enhancement plan was disclosed - The company has formulated a "Market Value Management System" but has not disclosed a valuation enhancement plan[91](index=91&type=chunk) [13. Implementation of "Quality and Return Dual Improvement" Action Plan](index=23&type=section&id=十三、“质量回报双提升”行动方案贯彻落实情况) The company did not disclose an announcement regarding the "Quality and Return Dual Improvement" action plan - The company did not disclose an announcement regarding the "Quality and Return Dual Improvement" action plan[92](index=92&type=chunk) [Part IV Corporate Governance, Environment, and Society](index=23&type=section&id=第四节%20公司治理、环境和社会) This section outlines the company's governance structure, environmental disclosures, and social responsibility initiatives [1. Changes in Directors, Supervisors, and Senior Management](index=23&type=section&id=一、公司董事、监事、高级管理人员变动情况) During the reporting period, the company's employee representative supervisor, Wang Hong, resigned due to personal reasons, and Ma Li was elected as the new employee representative supervisor Changes in Directors, Supervisors, and Senior Management | Name | Position Held | Type | Date | Reason | | :--- | :--- | :--- | :--- | :--- | | Wang Hong | Employee Representative Supervisor | Resignation | January 06, 2025 | Personal reasons | | Ma Li | Employee Representative Supervisor | Election | January 06, 2025 | Job transfer | [2. Profit Distribution and Capital Reserve Conversion to Share Capital for the Current Reporting Period](index=23&type=section&id=二、本报告期利润分配及资本公积金转增股本情况) The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the semi-annual period - The company plans not to distribute cash dividends, bonus shares, or convert capital reserves into share capital for the semi-annual period[95](index=95&type=chunk) [3. Implementation of Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures](index=24&type=section&id=三、公司股权激励计划、员工持股计划或其他员工激励措施的实施情况) The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures and their implementation during the reporting period - The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures during the reporting period[96](index=96&type=chunk) [4. Environmental Information Disclosure](index=25&type=section&id=四、环境信息披露情况) The company and its main subsidiaries, Hunan Erkang Pharmaceutical Co., Ltd. and Hunan Xiangyikang Pharmaceutical Co., Ltd., have been included in the list of enterprises required to disclose environmental information by law and have disclosed environmental information as required - The company and Hunan Xiangyikang Pharmaceutical Co., Ltd. have been included in the list of enterprises required to disclose environmental information by law, and their reports can be queried in the designated system[97](index=97&type=chunk) [5. Social Responsibility](index=25&type=section&id=五、社会责任情况) Adhering to its core values of "harmony, loyalty, diligence, and performance," the company actively fulfills its responsibilities to shareholders, employees, customers, suppliers, and society, promoting harmonious development with all stakeholders - The company safeguards shareholder rights by establishing sound internal management and control systems, strictly disclosing information, and standardizing general meeting procedures[99](index=99&type=chunk) - The company values employee career development, provides equal opportunities, ensures safe production and physical and mental health, improves human resource management systems, and offers diverse cultural and recreational activities[100](index=100&type=chunk) - Adhering to its mission of "everything for drug safety," the company strictly controls product quality, establishes a comprehensive supplier evaluation system, and protects the rights and interests of customers and suppliers[101](index=101&type=chunk) - The company places high importance on environmental protection and safety, implementing a "safety and environmental protection" year-end veto system, paying taxes in accordance with the law, and actively participating in public welfare activities[102](index=102&type=chunk) [Part V Significant Matters](index=27&type=section&id=第五节%20重要事项) This section details significant events, including commitments, related party transactions, litigation, and other material developments [1. Commitments Fulfilled and Overdue Unfulfilled by Controlling Shareholder, Shareholders, Related Parties, Acquirers, and the Company During and as of the End of the Reporting Period](index=27&type=section&id=一、公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内履行完毕及截至报告期末超期未履行完毕的承诺事项) During the reporting period, there were no commitments fulfilled or overdue unfulfilled by the company's actual controller, shareholders, related parties, acquirers, or the company itself - The company had no commitments fulfilled or overdue unfulfilled during the reporting period[104](index=104&type=chunk) [2. Non-Operating Funds Occupied by Controlling Shareholder and Other Related Parties from the Listed Company](index=27&type=section&id=二、控股股东及其他关联方对上市公司的非经营性占用资金情况) During the reporting period, there were no non-operating funds occupied by the controlling shareholder and other related parties from the listed company - The company had no non-operating funds occupied by the controlling shareholder and other related parties during the reporting period[105](index=105&type=chunk) [3. Irregular External Guarantees](index=27&type=section&id=三、违规对外担保情况) The company had no irregular external guarantees during the reporting period - The company had no irregular external guarantees during the reporting period[106](index=106&type=chunk) [4. Appointment and Dismissal of Accounting Firms](index=27&type=section&id=四、聘任、解聘会计师事务所情况) The company's semi-annual report was not audited - The company's semi-annual report was unaudited[107](index=107&type=chunk) [5. Explanations by the Board of Directors, Supervisory Board, and Audit Committee on the Accounting Firm's "Non-Standard Audit Report" for the Current Reporting Period](index=27&type=section&id=五、董事会、监事会、审计委员会对会计师事务所本报告期“非标准审计报告”的说明) During the reporting period, there were no explanations by the board of directors, supervisory board, or audit committee regarding a "non-standard audit report" from the accounting firm for the current reporting period - The company had no "non-standard audit report" explanations during the reporting period[108](index=108&type=chunk) [6. Explanations by the Board of Directors on Matters Related to the "Non-Standard Audit Report" for the Prior Year](index=27&type=section&id=六、董事会对上年度“非标准审计报告”相关情况的说明) During the reporting period, there were no explanations by the board of directors regarding matters related to the "non-standard audit report" for the prior year - The company had no prior year "non-standard audit report" explanations during the reporting period[108](index=108&type=chunk) [7. Bankruptcy Reorganization Matters](index=27&type=section&id=七、破产重整相关事项) The company had no bankruptcy reorganization matters during the reporting period - The company had no bankruptcy reorganization matters during the reporting period[108](index=108&type=chunk) [8. Litigation Matters](index=27&type=section&id=八、诉讼事项) The company had no significant litigation or arbitration matters during the reporting period, though other litigation matters include multiple contract disputes, some settled or won, others ongoing, involving significant amounts - The company had no significant litigation or arbitration matters during the reporting period[109](index=109&type=chunk) Other Litigation Matters Overview | Litigation Type | Amount Involved (RMB 10,000) | Progress | Outcome and Impact | | :--- | :--- | :--- | :--- | | Plaintiff Cases (1 case) | 46.80 | Concluded | Contract dispute settled through mediation, both parties fulfilled obligations | | Plaintiff Cases (8 cases) | 6,283.96 | Concluded | 3 contract disputes won; 5 contract disputes settled through mediation, defendant compensated | | Defendant Cases (7 cases) | 10.53 | Concluded | 1 contract dispute won on retrial; 2 contract disputes settled through mediation and paid; 1 labor dispute settled through mediation and paid; 3 disputes withdrawn by plaintiff | | Defendant Cases (3 cases) | 187.06 | 2 concluded | 2 contract disputes settled through mediation; 1 bill recourse dispute concluded by judgment | | Defendant Cases (1 case) | 1,299.35 | Trial stage | 1 liability dispute under second-instance trial | [9. Penalties and Rectification](index=28&type=section&id=九、处罚及整改情况) The company had no penalties or rectification situations during the reporting period - The company had no penalties or rectification situations during the reporting period[111](index=111&type=chunk) [10. Integrity Status of the Company, its Controlling Shareholder, and Actual Controller](index=28&type=section&id=十、公司及其控股股东、实际控制人的诚信状况) During the reporting period, there were no integrity issues concerning the company, its controlling shareholder, or actual controller - The company had no integrity issues during the reporting period[112](index=112&type=chunk) [11. Significant Related Party Transactions](index=28&type=section&id=十一、重大关联交易) During the reporting period, the company had no related party transactions related to daily operations, asset or equity acquisitions/disposals, joint external investments, related party creditor-debtor relationships, or dealings with affiliated financial companies - The company had no related party transactions related to daily operations during the reporting period[112](index=112&type=chunk) - The company had no related party transactions involving asset or equity acquisitions/disposals during the reporting period[113](index=113&type=chunk) - The company had no related party transactions involving joint external investments during the reporting period[114](index=114&type=chunk) - The company had no related party creditor-debtor relationships during the reporting period[115](index=115&type=chunk) - The company and its controlled financial companies had no deposits, loans, credit lines, or other financial business with related parties[116](index=116&type=chunk)[117](index=117&type=chunk) - The company had no other significant related party transactions during the reporting period[118](index=118&type=chunk) [12. Significant Contracts and Their Performance](index=29&type=section&id=十二、重大合同及其履行情况) The company had no entrustment, contracting, or leasing matters during the reporting period, but provided a total guarantee limit of **RMB 1.5 billion** for its subsidiaries, with an actual amount of **RMB 95.75 million**, of which **RMB 55.75 million** was provided to guaranteed entities with a debt-to-asset ratio exceeding 70% - The company had no entrustment, contracting, or leasing situations during the reporting period[119](index=119&type=chunk)[120](index=120&type=chunk)[121](index=121&type=chunk) Company Guarantees for Subsidiaries | Guaranteed Entity Name | Guaranteed Limit (RMB 10,000) | Actual Guaranteed Amount (RMB 10,000) | Guarantee Type | Fulfilled | | :--- | :--- | :--- | :--- | :--- | | Sukang Bio | 10,000 | 3,000 | Joint and several liability guarantee | No | | Xianglilai | 60,000 | 5,575 | Joint and several liability guarantee | No | | Hong Kong Erkang | 20,000 | 0 | - | - | | Xiangyikang | 25,000 | 0 | - | - | | Suerkang | 10,000 | 0 | - | - | | Guangyu Limin | 25,000 | 0 | - | - | | Total Approved Guarantee Limit for Subsidiaries at Period-end | 150,000 | - | - | - | | Total Actual Guarantee Balance for Subsidiaries at Period-end | - | 9,575 | - | - | | Proportion of Total Actual Guarantee to Company's Net Assets | - | 2.14% | - | - | | Of which: Debt Guarantees Provided Directly or Indirectly to Guaranteed Entities with Debt-to-Asset Ratio Exceeding 70% | - | 5,575 | - | - | - The company had no significant contracts related to daily operations or other significant contracts during the reporting period[126](index=126&type=chunk)[127](index=127&type=chunk) [13. Explanation of Other Significant Matters](index=31&type=section&id=十三、其他重大事项的说明) The preliminary preparation work for the comprehensive formulation production project invested by the company's controlling subsidiary, Erkang Tanzania Co., Ltd., has been completed, with trial production expected in the fourth quarter of 2025, and drug registration applications to be submitted concurrently, while equipment for the roasting project invested by Fenghuang Industrial has arrived at the plant and is being installed - Erkang Tanzania Co., Ltd.'s comprehensive formulation production project has completed preliminary preparations, with drug workshop design drawings approved, and trial production is expected in the fourth quarter of 2025[128](index=128&type=chunk) - The company has selected **200** solid formulation varieties and is preparing drug registration materials, intending to submit applications concurrently with project completion[128](index=128&type=chunk) - Equipment for the roasting project invested by Fenghuang Industrial has arrived at the plant and is being installed[128](index=128&type=chunk) [14. Significant Matters of Company Subsidiaries](index=31&type=section&id=十四、公司子公司重大事项) The company established a wholly-owned subsidiary, Hunan Guanhe Technology Co., Ltd., which in turn established a controlling subsidiary, Hangzhou Langde Intelligent Technology Co., Ltd., primarily engaged in investments in new quality productive forces and AI application software development, and the subsidiary Yiyang Datonghu Suyikang Pharmaceutical Co., Ltd. has completed its deregistration - The company established a wholly-owned subsidiary, Hunan Guanhe Technology Co., Ltd., with a registered capital of **RMB 10 million**, primarily engaged in investments in new quality productive forces[129](index=129&type=chunk) - Hunan Guanhe Technology Co., Ltd. established a controlling subsidiary, Hangzhou Langde Intelligent Technology Co., Ltd., holding **51%** of its shares, primarily engaged in AI application software development and intelligent robot R&D[129](index=129&type=chunk) - The company's subsidiary, Yiyang Datonghu Suyikang Pharmaceutical Co., Ltd., has completed its deregistration[130](index=130&type=chunk) [Part VI Share Changes and Shareholder Information](index=32&type=section&id=第六节%20股份变动及股东情况) This section details changes in the company's share capital, shareholder structure, and information on directors, supervisors, and senior management shareholdings [1. Share Changes](index=32&type=section&id=一、股份变动情况) During the reporting period, the company's total share capital remained unchanged, and the proportions of restricted and unrestricted shares remained constant, with no changes in restricted shares held by directors, supervisors, and senior management Share Changes | Item | Number of Shares Before This Change (shares) | Proportion Before This Change | Increase/Decrease in This Change (+,-) | Number of Shares After This Change (shares) | Proportion After This Change | | :--- | :--- | :--- | :--- | :--- | :--- | | I. Restricted Shares | 640,212,979 | 31.04% | 0 | 640,212,979 | 31.04% | | II. Unrestricted Shares | 1,422,391,891 | 68.96% | 0 | 1,422,391,891 | 68.96% | | III. Total Shares | 2,062,604,870 | 100.00% | 0 | 2,062,604,870 | 100.00% | Changes in Restricted Shares | Shareholder Name | Restricted Shares at Beginning of Period (shares) | Restricted Shares Released in Current Period (shares) | Restricted Shares Increased in Current Period (shares) | Restricted Shares at End of Period (shares) | Reason for Restriction | | :--- | :--- | :--- | :--- | :--- | :--- | | Shuai Fangwen | 640,181,179 | 0 | 0 | 640,181,179 | Restricted during tenure as Director, Supervisor, or Senior Management | | Gu Jishun | 26,850 | 0 | 0 | 26,850 | Restricted during tenure as Director, Supervisor, or Senior Management | | Luo Haijian | 4,950 | 0 | 0 | 4,950 | Restricted during tenure as Director, Supervisor, or Senior Management | | Total | 640,212,979 | 0 | 0 | 640,212,979 | - | [2. Securities Issuance and Listing](index=33&type=section&id=二、证券发行与上市情况) The company had no securities issuance or listing during the reporting period - The company had no securities issuance or listing during the reporting period[136](index=136&type=chunk) [3. Number of Shareholders and Shareholding Information](index=33&type=section&id=三、公司股东数量及持股情况) At the end of the reporting period, the total number of common shareholders was **42,746**, with Shuai Fangwen holding **41.38%** and Hunan Shuaijia Investment Co., Ltd. holding **6.45%**, and shares held by both are pledged - The total number of common shareholders at the end of the reporting period was **42,746**[137](index=137&type=chunk) Shareholding Information of Shareholders Holding 5% or More or Top 10 Shareholders | Shareholder Name | Shareholder Nature | Shareholding Percentage | Number of Shares Held at End of Reporting Period (shares) | Number of Restricted Shares Held (shares) | Number of Unrestricted Shares Held (shares) | Share Status | Quantity (shares) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Shuai Fangwen | Domestic Natural Person | 41.38% | 853,574,906 | 640,181,179 | 213,393,727 | Pledged | 834,664,800 | | Hunan Shuaijia Investment Co., Ltd. | Domestic Non-State-Owned Legal Person | 6.45% | 132,951,004 | 0 | 132,951,004 | Pledged | 131,515,200 | | Peng Xingni | Domestic Natural Person | 2.54% | 52,427,048 | 0 | 52,427,048 | Frozen | 52,427,048 | - Mr. Shuai Fangwen and Ms. Cao Zaiyun, the controlling shareholder, legal representative, chairman, and general manager of Hunan Shuaijia Investment, are married[138](index=138&type=chunk) [4. Changes in Shareholdings of Directors, Supervisors, and Senior Management](index=34&type=section&id=四、董事、监事和高级管理人员持股变动) There were no changes in the shareholdings of the company's directors, supervisors, and senior management during the reporting period - There were no changes in the shareholdings of the company's directors, supervisors, and senior management during the reporting period[140](index=140&type=chunk) [5. Changes in Controlling Shareholder or Actual Controller](index=35&type=section&id=五、控股股东或实际控制人变更情况) The company's controlling shareholder and actual controller remained unchanged during the reporting period - The company's controlling shareholder remained unchanged during the reporting period[141](index=141&type=chunk) - The company's actual controller remained unchanged during the reporting period[141](index=141&type=chunk) [6. Preferred Share Information](index=36&type=section&id=六、优先股相关情况) The company had no preferred shares during the reporting period - The company had no preferred shares during the reporting period[142](index=142&type=chunk) [Part VII Bond-Related Information](index=37&type=section&id=第七节%20债券相关情况) The company had no bond-related information during the reporting period - The company had no bond-related information during the reporting period[144](index=144&type=chunk) [Part VIII Financial Report](index=38&type=section&id=第八节%20财务报告) This section presents the company's comprehensive financial statements, including balance sheets, income statements, cash flow statements, and statements of changes in owners' equity [1. Audit Report](index=38&type=section&id=一、审计报告) The company's semi-annual financial report was unaudited - The company's semi-annual financial report was unaudited[146](index=146&type=chunk) [2. Financial Statements](index=38&type=section&id=二、财务报表) This section provides the company's consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owners' equity for the first half of 2025, comprehensively presenting the company's financial position, operating results, and cash flow situation - The consolidated balance sheet shows total assets of **RMB 5.05 billion** and owners' equity attributable to the parent company of **RMB 4.47 billion** at period-end[150](index=150&type=chunk) - The consolidated income statement shows total operating revenue of **RMB 681.88 million** and net profit attributable to parent company shareholders of **RMB 37.63 million** for the current period[157](index=157&type=chunk) - The consolidated cash flow statement shows net cash flow from operating activities of **RMB 45.84 million**, net cash flow from investing activities of **negative RMB 104.94 million**, and net cash flow from financing activities of **negative RMB 65.92 million**[163](index=163&type=chunk) [2.1. Consolidated Balance Sheet](index=38&type=section&id=1、合并资产负债表) As of June 30, 2025, the company's consolidated total assets were **RMB 5.05 billion**, total liabilities were **RMB 634.44 million**, and total owners' equity was **RMB 4.42 billion**, of which **RMB 4.47 billion** was attributable to parent company owners Consolidated Balance Sheet Key Data (June 30, 2025) | Item | Period-end Balance (RMB) | Beginning Balance (RMB) | | :--- | :--- | :--- | | Total Assets | 5,049,890,880.73 | 5,199,734,491.19 | | Total Liabilities | 634,442,919.26 | 797,540,680.70 | | Total Owners' Equity Attributable to Parent Company | 4,469,540,895.52 | 4,447,425,532.36 | | Minority Interests | -54,092,934.05 | -45,231,721.87 | | Total Owners' Equity | 4,415,447,961.47 | 4,402,193,810.49 | [2.2. Parent Company Balance Sheet](index=40&type=section&id=2、母公司资产负债表) As of June 30, 2025, the parent company's total assets were **RMB 4.93 billion**, total liabilities were **RMB 1.03 billion**, and total owners' equity was **RMB 3.89 billion** Parent Company Balance Sheet Key Data (June 30, 2025) | Item | Period-end Balance (RMB) | Beginning Balance (RMB) | | :--- | :--- | :--- | | Total Assets | 4,925,253,026.10 | 5,276,951,518.42 | | Total Liabilities | 1,034,319,116.13 | 1,422,643,905.83 | | Total Owners' Equity | 3,890,933,909.97 | 3,854,307,612.59 | [2.3. Consolidated Income Statement](index=42&type=section&id=3、合并利润表) For the first half of 2025, the company's consolidated total operating revenue was **RMB 681.88 million**, a year-over-year increase of 9.74%, and net profit attributable to parent company shareholders was **RMB 37.63 million**, a significant year-over-year increase of 497.36% Consolidated Income Statement Key Data (First Half of 2025) | Item | First Half of 2025 (RMB) | First Half of 2024 (RMB) | | :--- | :--- | :--- | | Total Operating Revenue | 681,881,688.38 | 621,346,708.93 | | Operating Profit | 32,112,145.26 | 11,734,714.77 | | Total Profit | 32,053,479.38 | 8,634,864.55 | | Net Profit | 28,810,557.54 | 6,338,336.65 | | Net Profit Attributable to Parent Company Shareholders | 37,634,642.58 | 6,300,155.19 | | Minority Interests | -8,824,085.04 | 38,181.46 | | Basic Earnings Per Share (RMB/share) | 0.0182 | 0.0031 | [2.4. Parent Company Income Statement](index=44&type=section&id=4、母公司利润表) For the first half of 2025, the parent company's operating revenue was **RMB 268.84 million**, and net profit was **RMB 36.34 million**, a year-over-year decrease Parent Company Income Statement Key Data (First Half of 2025) | Item | First Half of 2025 (RMB) | First Half of 2024 (RMB) | | :--- | :--- | :--- | | Operating Revenue | 268,843,590.10 | 288,246,851.78 | | Operating Profit | 37,230,901.08 | 46,366,994.69 | | Total Profit | 37,228,946.08 | 46,441,023.45 | | Net Profit | 36,337,500.49 | 45,231,142.85 | [2.5. Consolidated Cash Flow Statement](index=45&type=section&id=5、合并现金流量表) For the first half of 2025, the company's net cash flow from operating activities was **RMB 45.84 million**, a year-over-year decrease of 64.08%, net cash flow from investing activities was **negative RMB 104.94 million**, and net cash flow from financing activities was **negative RMB 65.92 million**, resulting in a net decrease in cash and cash equivalents of **negative RMB 126.57 million** Consolidated Cash Flow Statement Key Data (First Half of 2025) | Item | First Half of 2025 (RMB) | First Half of 2024 (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 45,842,247.53 | 127,628,976.65 | | Net Cash Flow from Investing Activities | -104,941,146.23 | -197,337,778.52 | | Net Cash Flow from Financing Activities | -65,915,412.21 | 141,354,713.02 | | Net Increase in Cash and Cash Equivalents | -126,569,773.22 | 63,727,424.61 | | Cash and Cash Equivalents at End of Period | 363,339,251.56 | 574,365,150.97 | [2.6. Parent Company Cash Flow Statement](index=46&type=section&id=6、母公司现金流量表) For the first half of 2025, the parent company's net cash flow from operating activities was **RMB 44.77 million**, net cash flow from investing activities was **negative RMB 50.83 million**, and net cash flow from financing activities was **negative RMB 4.67 million**, resulting in a net decrease in cash and cash equivalents of **negative RMB 11.88 million** Parent Company Cash Flow Statement Key Data (First Half of 2025) | Item | First Half of 2025 (RMB) | First Half of 2024 (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 44,765,812.46 | 169,535,791.96 | | Net Cash Flow from Investing Activities | -50,826,357.15 | -110,534,141.26 | | Net Cash Flow from Financing Activities | -4,673,772.23 | 98,465,899.99 | | Net Increase in Cash and Cash Equivalents | -11,878,737.90 | 157,203,197.18 | | Cash and Cash Equivalents at End of Period | 73,606,508.39 | 234,759,099.94 | [2.7. Consolidated Statement of Changes in Owners' Equity](index=47&type=section&id=7、合并所有者权益变动表) For the first half of 2025, the company's consolidated total owners' equity increased by **RMB 13.25 million**, primarily due to an increase in total comprehensive income attributable to parent company owners and changes in minority interests - Total comprehensive income attributable to parent company owners for this period was **RMB 21.83 million**, and total comprehensive income attributable to minority interests was **negative RMB 8.86 million**[168](index=168&type=chunk) - Consolidated total owners' equity at period-end was **RMB 4.42 billion**, an increase of **RMB 13.25 million** from the beginning of the period[169](index=169&type=chunk) [2.8. Parent Company Statement of Changes in Owners' Equity](index=51&type=section&id=8、母公司所有者权益变动表) For the first half of 2025, the parent company's total owners' equity increased by **RMB 36.63 million**, primarily due to an increase in total comprehensive income - Total comprehensive income for the parent company in this period was **RMB 36.34 million**[173](index=173&type=chunk) - Parent company total owners' equity at period-end was **RMB 3.89 billion**, an increase of **RMB 36.63 million** from the beginning of the period[174](index=174&type=chunk) [3. Company Overview](index=54&type=section&id=三、公司基本情况) Hunan Erkang Pharmaceutical Co., Ltd. was registered on November 8, 2010, and listed on the Shenzhen Stock Exchange on September 27, 2011, primarily engaged in the production and sales of APIs, chemical products, food additives, chemical pharmaceutical preparations, starch and starch products, as well as pharmaceutical raw materials, excipients, medicinal capsules, and health foods - The company was registered on November 8, 2010, and listed on the Shenzhen Stock Exchange on September 27, 2011[178](index=178&type=chunk) - The company belongs to the pharmaceutical manufacturing industry, with main business activities including the production and sales of APIs, excipients, finished drugs, and new energy materials[178](index=178&type=chunk) [4. Basis of Financial Statement Preparation](index=54&type=section&id=四、财务报表的编制基础) The company's financial statements are prepared on a going concern basis, and there are no matters or circumstances that would cause significant doubt about its ability to continue as a going concern within 12 months from the end of the reporting period - The company's financial statements are prepared on a going concern basis[179](index=179&type=chunk) - There are no matters or circumstances that would cause significant doubt about the company's ability to continue as a going concern within 12 months from the end of the reporting period[180](index=180&type=chunk) [5. Significant Accounting Policies and Accounting Estimates](index=55&type=section&id=五、重要会计政策及会计估计) This section details the company's compliance with enterprise accounting standards, accounting period, operating cycle, functional currency, materiality criteria, business combinations, consolidated financial statement preparation, financial instruments, various receivables, inventories, asset impairment, revenue recognition, government grants, deferred income tax, leasing, and other significant accounting policies and estimates, noting a change in accounting estimate for the expected credit loss rate of accounts receivable during the reporting period - The company's financial statements comply with enterprise accounting standards, accurately and completely reflecting its financial position, operating results, and cash flows[182](index=182&type=chunk) - The company has formulated specific accounting policies and estimates for financial instrument impairment, inventory, fixed asset depreciation, and revenue recognition based on its actual production and operating characteristics[181](index=181&type=chunk) - The company changed its accounting estimate for the expected credit loss rate of accounts receivable on January 1, 2025, to more objectively and fairly reflect its financial position[260](index=260&type=chunk) [6. Taxation](index=73&type=section&id=六、税项) This section discloses the company's main tax categories and rates, including VAT, urban maintenance and construction tax, and corporate income tax, with the company and some subsidiaries enjoying high-tech enterprise income tax preferential policies, and some overseas subsidiaries and small-profit enterprises also enjoying local or national tax incentives Main Tax Categories and Rates | Tax Category | Tax Rate | | :--- | :--- | | Value-Added Tax | 13%, 9%, 6%, 5% | | Urban Maintenance and Construction Tax | 7%, 5% | | Corporate Income Tax | 30%, 25%, 20%, 16.50%, 15% | | Property Tax | 12%, 1.2% | | Education Surcharge | 3% | | Local Education Surcharge | 2% | - The company, Hunan Xiangyikang Pharmaceutical Co., Ltd., and Hunan Sunang Health Technology Co., Ltd. are recognized as high-tech enterprises and enjoy a **15%** corporate income tax preferential rate[263](index=263&type=chunk) - Tibet Changdu Guangyu Limin Pharmaceutical Co., Ltd. enjoys the Western Development policy, with corporate income tax levied at a **15%** rate[264](index=264&type=chunk) - Fenghuang Industrial Co., Ltd. is in a profit tax exemption period, Xulongqi Co., Ltd. is in a critical period, and Changsha Lushengyuan International Trade Co., Ltd. enjoys corporate income tax benefits for small and micro enterprises[265](index=265&type=chunk) [7. Notes to Consolidated Financial Statement Items](index=74&type=section&id=七、合并财务报表项目注释) This section provides detailed information on each item in the consolidated financial statements, including monetary funds, various receivables, inventories, fixed assets, intangible assets, goodwill, short-term borrowings, accounts payable, employee compensation payable, operating revenue and costs, various expenses, investment income, asset impairment losses, etc., with explanations for significant changes - Period-end monetary funds totaled **RMB 492.52 million**, including restricted funds such as bank acceptance bill deposits of **RMB 80 million** and letter of credit deposits of **RMB 30.66 million**[267](index=267&type=chunk) - Accounts receivable period-end balance was **RMB 162.70 million**, an increase of **57.69%** from the beginning of the period, primarily due to increased sales revenue in the current period[283](index=283&type=chunk)[287](index=287&type=chunk) - Inventory period-end balance was **RMB 625 million**, an increase of **4.09%** from the beginning of the period, including development costs of **RMB 154 million**[349](index=349&type=chunk) - Short-term borrowings period-end balance was **RMB 310.08 million**, a decrease of **36.48%** from the beginning of the period, primarily due to repayment of maturing bank short-term borrowings[437](index=437&type=chunk) - Operating revenue was **RMB 681.88 million**, operating cost was **RMB 494.46 million**, selling expenses decreased by **50.66%** year-over-year, and financial expenses increased by **187.21%** year-over-year[498](index=498&type=chunk)[507](index=507&type=chunk)[510](index=510&type=chunk) [8. Research and Development Expenses](index=126&type=section&id=八、研发支出) The company's total R&D expenditure for the current period was **RMB 19.94 million**, all expensed, primarily for material consumption and employee compensation, with no R&D projects meeting capitalization criteria R&D Expenditure Details | Item | Amount for Current Period (RMB) | Amount for Prior Period (RMB) | | :--- | :--- | :--- | | Material Consumption | 11,316,566.66 | 11,038,419.66 | | Employee Compensation | 6,453,762.71 | 6,494,682.17 | | Intangible Asset Amortization | 1,066,826.24 | 1,322,480.70 | | Depreciation Expense | 1,055,987.15 | 1,158,330.22 | | Other | 43,480.06 | 1,181,943.40 | | Total | 19,936,622.82 | 21,195,856.15 | | Of which: Expensed R&D Expenditure | 19,936,622.82 | 21,195,856.15 | - All R&D expenditure for this period was expensed, with no R&D projects meeting capitalization criteria[561](index=561&type=chunk)[562](index=562&type=chunk) [9. Changes in Consolidation Scope](index=127&type=section&id=九、合并范围的变更) During the reporting period, the company's consolidation scope increased due to the establishment of new subsidiaries Hunan Guanhe Technology Co., Ltd. and its controlling subsidiary Hangzhou Langde Intelligent Technology Co., Ltd., and decreased due to the deregistration of Yiyang Datonghu Suyikang Pharmaceutical Co., Ltd. - The company established a wholly-owned subsidiary, Hunan Guanhe Technology Co., Ltd., and a controlling subsidiary, Hangzhou Langde Intelligent Technology Co., Ltd., increasing the consolidation scope[129](index=129&type=chunk)[571](index=571&type=chunk) - The company deregistered Yiyang Datonghu Suyikang Pharmaceutical Co., Ltd., reducing the consolidation scope[130](index=130&type=chunk)[571](index=571&type=chunk) [10. Interests in Other Entities](index=130&type=section&id=十、在其他主体中的权益) This section discloses the company's interests in subsidiaries, joint ventures, and associates, noting that the company owns multiple wholly-owned or controlling subsidiaries and holds interests in associates, with some important non-wholly-owned subsidiaries having minority interests and losses - The company owns multiple wholly-owned or controlling subsidiaries, including Hunan Xianglilai Chemical Co., Ltd., Hunan Xiangyikang Pharmaceutical Co., Ltd., and Hunan Erkang (Hong Kong) Co., Ltd.[573](index=573&type=chunk)[574](index=574&type=chunk) Important Non-Wholly-Owned Subsidiaries | Subsidiary Name | Minority Shareholding Percentage | Profit or Loss Attributable to Minority Shareholders in Current Period (RMB) | Minority Interests Balance at Period-end (RMB) | | :--- | :--- | :--- | :--- | | Wangkang Biochemical | 30.00% | -2,465,592.71 | -17,663,551.11 | | Guangyu Limin | 49.00% | -4,228,145.08 | -25,379,430.59 | - The company holds a **48.00%** stake in Yiyang Tongyi Pharmaceutical Partnership (Limited Partnership), accounted for using the equity method[581](index=581&type=chunk) [11. Government Grants](index=135&type=section&id=十一、政府补助) At the end of the reporting period, the company's deferred income included government grants related to assets totaling **RMB 12.46 million**, and government grants recognized in other income for the current period amounted to **RMB 3.80 million** Liability Items Involving Government Grants | Accounting Account | Beginning Balance (RMB) | Decrease in Current Period (RMB) | Period-end Balance (RMB) | Asset/Income Related | | :--- | :--- | :--- | :--- | :--- | | Deferred Income | 14,929,804.05 | 2,466,499.71 | 12,463,304.34 | Asset Related | - Government grants recognized in other income for the current period amounted to **RMB 3.80 million**, compared to **RMB 9.67 million** in the prior period[591](index=591&type=chunk) [12. Risks Related to Financial Instruments](index=136&type=section&id=十二、与金融工具相关的风险) The company faces credit risk, liquidity risk, and market risk (including interest rate risk and foreign exchange risk), which it manages through credit assessment, customer diversification, bank credit lines, optimizing financing structure, and monitoring foreign currency exposure, and transferred some financial assets through bill endorsement during the reporting period - The company faces credit risk, liquidity risk, and market risk (interest rate
尔康制药维生素B6注射液通过仿制药一致性评价
Quan Jing Wang· 2025-08-13 05:51
Core Viewpoint - Erkang Pharmaceutical has received approval from the National Medical Products Administration for its Vitamin B6 injection, which has passed the consistency evaluation of quality and efficacy for generic drugs, enhancing its market competitiveness and potential for sales growth [1] Group 1: Product Approval - The company announced that its Vitamin B6 injection (1ml:100mg) has been approved, which is primarily used for the prevention and treatment of Vitamin B6 deficiency and related conditions [1] - The approval is expected to positively impact the market expansion and sales of the related products [1] Group 2: Market Reaction - Following the announcement, Erkang Pharmaceutical's stock price increased by 7.17%, closing at 3.44 yuan per share [1]
7月29日晚间重要公告一览
Xi Niu Cai Jing· 2025-07-29 10:14
Group 1 - Anhui Construction won a joint bid for the Chongqing Rongchang to Sichuan Zigong expressway project, with a total estimated investment of 3.614 billion yuan and a construction period of 3 years [1] - Hongfa Co. reported a net profit of 964 million yuan for the first half of 2025, a year-on-year increase of 14.19%, with revenue of 8.347 billion yuan, up 15.43% [1][2] - Lujiazui's net profit for the first half of 2025 was 815 million yuan, a decrease of 7.87%, despite a revenue increase of 33.91% to 6.598 billion yuan [3] - Enhua Pharmaceutical achieved a net profit of 700 million yuan, up 11.38%, with revenue of 3.010 billion yuan, an increase of 8.93% [4][5] - China CNR signed several major contracts totaling approximately 32.92 billion yuan, covering various sectors including urban rail vehicles and wind power equipment [6] - WanTong Intelligent signed an exclusive sales and cooperation agreement in the embodied intelligence field, gaining global sales rights for specific chip-based products [7][8] Group 2 - Liansheng Technology's subsidiary received a government subsidy of 13.5 million yuan, accounting for 12.24% of the company's latest audited net profit [9] - Guobang Pharmaceutical reported a net profit of 456 million yuan, a year-on-year increase of 12.60%, with revenue of 3.026 billion yuan, up 4.63% [10] - Baotai expects a net loss of 110 to 140 million yuan for the first half of 2025, a reduction in loss compared to the previous year [11] - Sains expects a net profit decrease of 57.53% to 60.13%, with projected revenue growth of 15.17% to 23.59% [12] - Nanya New Materials anticipates a net profit of 80 to 95 million yuan for the first half of 2025, an increase compared to the previous year [13] - Tian Pharmaceutical's subsidiary passed the consistency evaluation for a peritoneal dialysis solution [14] Group 3 - Shede Liquor announced the resignation of director Ni Qiang due to work reasons [15] - Greentown Water plans to transfer assets and liabilities of its ASEAN subsidiary to improve resource allocation [16] - Beibu Gulf Port's subsidiary signed an associated transaction contract worth 11.199 million yuan [17] - Beibu Gulf Port announced multiple resignations of directors and executives [18] - Jidian Co. reported the resignation of its deputy general manager due to work changes [19] - Wanhua Chemical's industrial park in Fujian resumed production after maintenance [20] Group 4 - Shanghai Pharmaceuticals received approval for a clinical trial of a new indication for its B019 injection [21] - Jianbang Co. reported a net profit of 69.66 million yuan, a decrease of 27.72%, with revenue of 307 million yuan, down 15.37% [23] - Jianbang Co. plans to use up to 400 million yuan of idle funds for cash management [25] - Wanfu Bio's subsidiary obtained multiple medical device registrations [28] - Hunan Tianyan announced a change in its controlling shareholder to China Chang'an Automobile Group [29][30] - Xizhuang Co. plans to establish a joint venture for sustainable aviation fuel [32]